Bioxytran, Inc. Reports Positive Phase 1b/2a Clinical Study Results for ProLectin-M, a Broad-Range Antiviral Drug in Mild to Moderate COVID-19

Stock Information for MicroVision Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About MicroVision Inc.

Bioxytran Announces Positive Dose Optimization Results and Advances Toward Phase 3 Registrational Trial for ProLectin-M
Bioxytran Reports Positive Phase 2 Results Demonstrating Rapid Viral Clearance with ProLectin-MBioxytran
Bioxytran and University of Minnesota Launch Sponsored Research Collaboration to Advance Novel Carbohydrate-Based Therapeutics
Presenting on Emerging Growth Conference 88 Day 2 on December 11; Register to live stream
Bioxytran Announces Initiation of Coverage of its Stock by Independent Research
Bioxytran Completes Randomized Clinical Trial For its Broad-Spectrum Antiviral Drug
Bioxytran Unveils Revolutionary Precision Diagnostics on Tissue Oxygenation
Bioxytran's Breakthrough Broad-Spectrum Antiviral Technology Poised to Revolutionize Respiratory Infection Treatment

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.